End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
- USD | -.--% |
|
-.--% | -.--% |
May. 08 | Transcript : Odontoprev S.A., Q1 2024 Earnings Call, May 08, 2024 | |
May. 08 | Odontoprev S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- This company will be of major interest to investors in search of a high dividend stock.
Weaknesses
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- Most analysts recommend that the stock should be sold or reduced.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Sector: Managed Healthcare
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-.--% | 1.2B | - | ||
-8.31% | 5.65B | C |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- ODPV3 Stock
- ODPVY Stock
- Ratings Odontoprev S.A.